Assessment of ovarian reserve function in patients with adenomyosis and ovarian endometriosis by three-dimensional transvaginal ultrasound and Anti-Müllerian hormone

We evaluated the impact of adenomyosis and ovarian endometriosis on ovarian reserve function through transvaginal three-dimensional ultrasound and anti-mullerian hormone testing. A total of 150 female patients who were admitted to our hospital from January 2023 to May 2024 were selected; 58 cases had adenomyosis (adenomyosis group), 36 had ovarian endometriosis (ovarian endometriosis group), and 56 were healthy (healthy group). There were no statistically significant differences in clinical baseline data among the three groups (all P > 0.05). However, significant overall differences were found in anti-Mullerian hormone levels, antral follicle count, ovarian volume, vascularization index, flow index, and vascularization flow index among the three groups (F values were 90.34, 146.50, 92.61, 63.87, 59.50, 49.36 respectively; all P < 0.001); compared to the healthy group, these indicators were all decreased in the adenomyosis group and ovarian endometriosis group (all P < 0.05). Pearson correlation analysis revealed that serum anti-mullerian hormone levels were positively correlated with antral follicle count, ovarian volume, vascularization index, flow index, and vascularization flow index (r = 0.80, 0.73, 0.50, 0.48, 0.45, respectively; all P < 0.01). These data suggest that adenomyosis and ovarian endometriosis can lead to a decline in ovarian reserve function in women of reproductive age compared to their peers. Also, antral follicle count and ovarian volume are the optimal indicators for evaluating ovarian reserve function in these patients.